ELITE PHARMACEUTICALS INC /NV/ (ELTP)
As-reported financials and SEC filings for ELITE PHARMACEUTICALS INC /NV/. The latest annual period is FY2026. The latest reported quarter is Q1 FY2027. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
Snapshot
Fundamentals are from SEC filings for FY2026, the latest annual period (ended March 31, 2026). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Elite Pharmaceuticals Inc /nv/
- Revenue grew 77.1% to $149M in FY2026, faster than the 48.4% the year before.
- Operating margin is 33.0% in FY2026, +17.3 pp against 15.7% in FY2022.
- Most recent quarter Q1 FY2027: revenue $32M, down 19.5% from Q1 FY2026.
- Free cash flow was $23M in FY2026, 15.3% of revenue.
- Net income turned positive at $45M in FY2026, from a $4M loss in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Elite Pharmaceuticals Inc /nv/’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Elite Pharmaceuticals Inc /nv/’s return on equity of 45.4% ranks in the 95th percentile of the 167 pharmaceutical companies reporting it. Elite Pharmaceuticals Inc /nv/’s operating margin of 33.0% ranks in the 93rd percentile of the 113 pharmaceutical companies reporting it. Elite Pharmaceuticals Inc /nv/’s P/E of 5.8 ranks in the 12th percentile of the 60 peers with a meaningful P/E.
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-14 | 2.5M | -6.5% | 1.25 |
| 2026-07-31 | 2.7M | +3.3% | 3.73 |
| 2026-07-15 | 2.6M | -2.1% | 1.89 |
| 2026-06-30 | 2.7M | +2.3% | 2.05 |
| 2026-06-15 | 2.6M | -0.2% | 1.53 |
| 2026-05-29 | 2.6M | -0.9% | 3.24 |
| 2026-05-15 | 2.6M | +6.0% | 2.61 |
| 2026-04-30 | 2.5M | +1.6% | 2.13 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M | $14.8M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M | $5.1M |
| Net income | $44.9M | $-4.3M | $20.1M | $3.6M | $8.9M |
| Diluted EPS | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash and equivalents | $30.3M | $11.8M | $7.5M | $8.2M | $8.9M |
| Current assets | $112.1M | $57.7M | $40.0M | $21.5M | $18.9M |
| Total assets | $138.3M | $96.4M | $83.7M | $40.9M | $35.1M |
| Current liabilities | $17.4M | $11.8M | $13.0M | $7.8M | $6.7M |
| Long-term debt | — | — | — | — | $1.2M |
| Total liabilities | $39.4M | $42.9M | $26.1M | $11.9M | $9.9M |
| Total equity | $98.9M | $53.5M | $57.6M | $29.0M | $25.2M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Operating cash flow | $23.7M | $7.5M | $-3.2M | $3.3M | $6.5M |
| Capital expenditure | $925,626 | $1.6M | $809,653 | $5.7M | $498,566 |
| Free cash flow | $22.8M | $5.8M | $-4.0M | $-2.4M | $6.0M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2027 | $32.4M | -19.5% | $5.9M | — |
| Q4 FY2026 | $40.7M | 27.4% | $18.5M | $0.02 |
| Q3 FY2026 | $31.6M | 119.9% | $18.6M | $0.01 |
| Q2 FY2026 | $36.3M | 92.4% | $13.7M | $0.01 |
| Q1 FY2026 | $40.2M | 113.9% | $-5.9M | — |
| Q4 FY2025 | $32.0M | 78.3% | $17.0M | $0.02 |
| Q3 FY2025 | $14.4M | -7.6% | $-10.9M | $-0.01 |
| Q2 FY2025 | $18.9M | 33.4% | $-11.0M | $-0.01 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Selected SEC filings
Largest pharmaceutical peers
Monitor ELTP
Get an alert when Elite Pharmaceuticals Inc /nv/ files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor ELTP freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.